The report "Radioimmunoassay Market by Type (Reagents & Kits, Analyzers), End User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), and Geography - Global Forecast to 2020", The global radioimmunoassay (RIA) market was valued at $345.2 Million in 2014 and is expected to reach $428.4 Million by 2020, at a CAGR of 3.5% during the forecast period from 2015 to 2020.

Browse 75 market data Tables and 68 Figures spread through 113 Pages and in-depth TOC on "Radioimmunoassay Market”
http://www.marketsandmarkets.com/Market-Reports/radioimmunoassay-market-172815697.html
Early buyers will receive 10% customization on This report.

Radioimmunoassay (RIA) is an in-vitro assay technique that is used to measure the concentration of antigens in blood. RIA encompasses the separation of protein from a mixture by using the specificity of antibody- antigen binding and their quantitation by using radioactivity. The method is hypersensitive and can quantify tiny amounts of hormone or drug level with the help of antibodies.
Radioimmunoassay is used owing to its high sensitivity, which can analyze nanomolar and picomolar concentrations of hormones in biological fluids. RIA has become one of the major tools in various clinical laboratories for diagnostic procedures, such as assessing the plasma levels of most of the hormones, identifying the presence of certain abused drugs, evaluating the presence of hepatitis B surface antigen in donated blood, and others. This technique is also used for the early detection of cancer, treatment of peptic ulcers, research with neurotransmitters, detection of infections, and identification of allergens in food and house dust, and so on.
The increasing usage of RIA in pharmaceutical industries, research labs, and contract research organizations (CROs) has led to an increased demand of products that are based on this technique. Furthermore, the rising need for quality and error-free results to ensure patient satisfaction has resulted in research labs and diagnostic centers to opt for high-throughput and automated procedures. This is also one of the major factors that have resulted in the growth of the RIA market to a large extent.
There are two types of radioimmunoassay, which serve different functions for clinical diagnostics and research purposes. These types have been classified into reagents & kits and analyzers. In 2014, the reagents & kits segment contributed the largest share of 82.9% to the global radioimmunoassay market.
The various application areas of RIA are infectious disease testing, endocrine testing, allergy testing, oncology testing, toxicology testing, and autoimmune disease testing. Out of all the application segments, oncology testing is the largest application segment, and is expected to hold the major market share in the near future.
Based on this market’s end users, the global radioimmunoassay market has been segmented into hospitals (hospital-based laboratories/hospital-attached laboratories), academics, pharmaceutical industry and CROs, clinical laboratories, and others, which include physician offices, patient self-testing centers, blood banks, home health agencies, nursing homes, and ambulatory surgical centers.
The Sample Report For This Report@
http://www.marketsandmarkets.com/requestsample.asp?id=172815697
The global radioimmunoassay market has been categorized into major geographical regions, including Europe, North America, Asia, and the Rest of the world. Europe is the most dominant region in the global radioimmunoassay market, and contributed a share of 35.1% in 2014; the market in this region was valued at $121.5 Million in the same year.
Some of the major players in the radioimmunoassay globally are DIAsource ImmunoAssays SA (Belgium), Beckman Coulter, Inc. (U.S.), IBL International (A Tecan Company) (Germany), PerkinElmer, Inc. (U.S.), DRG International, Inc. (U.S.), MP Biomedicals, LLC (U.S.), Cisbio (France), Euro Diagnostica AB (Sweden), DiaSorin S.p.A.. (Italy), EMD Millipore (U.S.), Izotop (Hungary), Berthold Technologies GmbH & Co. KG (Germany), Stratec Biomedical AG (Germany), and others.

Get The PDF Brochure For This Report@
http://www.marketsandmarkets.com/pdfdownload.asp?id=172815697

About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: 1-888-600-6441